macro

Bausch + Lomb's BL1332 misses primary endpoint in Phase 2 ocular pain study

Bausch + Lomb reported Phase 2 results for BL1332 in post-surgical eye pain. The primary endpoint was missed, though no serious treatment-related adverse events occurred.

the same feed is available to bots and dashboards through the api. connect the api →

what happened

Bausch + Lomb has reported topline results from a Phase 2 study of BL1332, a first-in-class topical TRPV1 antagonist, in patients with pain after photorefractive keratectomy (PRK) surgery. The company announced the findings in a press release, which TradingView and Reuters carried. The study enrolled 129 adults, and it did not meet its primary endpoint of a statistically significant improvement over vehicle in the sum of pain intensity differences over 24 hours.

Still, both doses produced numerically greater pain relief than vehicle across the measures tested. At six hours, complete pain relief was reported by 14.0% and 14.6% of patients on the 0.30% and 0.15% doses, versus 3.7% on vehicle. Treatment-emergent adverse events occurred in 6.0% of patients on the 0.30% dose, 13.7% on the 0.15% dose and 14.8% on vehicle. There were no treatment-related serious adverse events.

The company is analyzing the full dataset and expects to discuss next steps with the U.S. Food and Drug Administration, including possible Phase 3 planning.

why it matters

The key point for investors is the missed primary endpoint: a statistically significant effect has not yet been shown, so the program's path will depend on talks with regulators. The story concerns a single drug from one company, so its market impact is limited to Bausch + Lomb shares.

market impact

Bausch + Lomb shares: missed primary endpoint weakens BL1332 outlook, pressure down

  • Bausch + Lomb shares pressure down — a missed primary endpoint casts doubt on the prospects of the BL1332 program

tags

instruments

Bausch + LombBL1332Bausch + Lomb shares

sources

  1. Bausch + Lomb Reports Phase 2 Findings for BL1332 in Post-Surgical Ocular Pain — TradingView, 19 November 2026 at 21:15 UTC
  2. Bausch + Lomb Reports Phase 2 Findings For Bl1332 In Post-Surgical Ocular Pain — Reuters, 19 November 2026 at 21:21 UTC
  3. Bausch + Lomb post-surgical ocular pain asset fails phase 2 main goal — Seeking Alpha, 19 November 2026 at 22:25 UTC

prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.

alerts on your topics, the morning digest and the api — in your account.

get stories in real time ↗